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ABSTRACT: Despite its beneficial role on insulin resistance and atherosclerosis, adiponectin has been frequently 
reported as an independent positive predictor of cardiovascular mortality. Very few information is available 
regarding adiponectin isoforms and mortality, in particular in advanced aging. Baseline serum levels of Total 
Adiponectin and its circulating isoforms (HMW-, MMW-, LMW-Adiponectin) were measured in 97 old patients 
(mean age: 79 years). Patients were followed up for all-cause mortality (study end-point) for an average of 76.4 ± 37.3 
months. A positive association was observed for LMW-Ad and all-cause mortality (HR: 1.13, 95% CI: 1.05-1,22, p: 
0.002). After multivariate adjustment for age, sex and a previous history of myocardial infarction, higher levels of 
LMW-Ad were significantly associated with all-cause mortality (HR: 1.11, 95% CI: 1.02-1.21; p: 0.017).  Interestingly 
neither total adiponectin neither the other two circulating isoforms (MMW- and HMW-Ad) showed any significant 
association with the study end-point. Our data suggest that the association between high serum adiponectin levels and 
increased mortality rate in elderly is contingent to an unbalanced circulating levels of adiponectin isoforms. The 
present results support the hypothesis that high levels of Low Molecular Weight adiponectin are a biomarker for 
mortality risk in very old patients. 
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Adiponectin, the most abundant adipose-tissue hormone 
with pleiotropic actions in a plethora of tissues, is an 
independent positive predictor of mortality in the general 
population, especially in cardiovascular setting [1]. 
Nevertheless, adiponectin exerts many insulin-sensitizing, 
anti-inflammatory and endothelial protective effects [1]. 
Because of such paradox, it is logical to suspect that total 
adiponectin (Tot-Ad) level may not be a marker of 
cardiovascular mortality risk. Actually, adiponectin 
circulates in the blood as three discrete oligomeric 
complexes known as high-, medium- and low-molecular-
weight adiponectin (HMW-, MMW- and LMW-Ad). 
While biological activities among these three isoforms are 
a matter of controversy, previous studies have indicated 
that HMW-, MMW- and LMW-Ad have different 
biological properties. However, the clinical data available 
on adiponectin isoforms are particularly restricted on its 
main isoform, the HMW-Ad, which is considered the 
active form [2].  
Although HMW-Ad is known to have strong 
vasculoprotective and insulin-sensitizing properties, the 
majority of studies measured only Tot-Ad circulating 
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levels; actually, only few studies have assessed the 
association of isomers levels and pathological conditions 
[3].  
We previously reported that Tot-Ad level was higher 
in older adults with previous coronary heart disease (CHD) 
but, among circulating isoforms, only LMW-Ad was 
significantly associated with CHD in elderly patients [4]. 
Based on this report, we used a long follow-up to 
investigate a possible independent association between 
adiponectin circulating isoforms and total mortality in a 
group of very old patients. 
 
MATERIALS AND METHODS 
 
This study was approved by the University of Tor Vergata 
Institutional-Review-Board and carried out in accordance 
with the principles of the Declaration of Helsinki as 
revised in 2000. Study patients were originally recruited 
for a clinical study which has been described in detail 
previously [4]. Follow-up information on outcome was 
collected yearly from 2002 to 2011 by a phone interview. 
The study outcome was all-cause mortality whose 
information was obtained and confirmed from patient’s 
primary care physicians, from death certificates or from 
review of web record (www.prescrizione. poslazio.it/ 
sismed-prescription/assistito). Follow-up data are 
available for 97 subjects (mean age 83±5.4y) since, of 108 
baseline individuals, 6 patients were excluded because 
their first-degree relatives disagreed to phone interview, 3 
because changed phone addresses and 2 due to home 
region changing.  
Smoking habits and history of hypertension, 
dyslipidemia and CHD as well as glucose-lowering 
treatment were also recorded at time of baseline 
examination. Data regarding medications were confirmed 
by review of medical records. 
Serum high-sensitivity C-reactive protein (hsCRP) 
levels were measured using a nephelometric assay (Dade-
Behring, Liederbach, Germany). Tumor necrosis factor 
alpha (TNF-α) levels were evaluated using enzyme-linked 
immunosorbent assay (ELISA) using commercially 
available kits (Bender MedSystem, Vienna, Austria). 
Adiponectin was measured using ELISA using a high-
sensitivity commercial kit for Tot-Ad, HMW-Ad, MMW-
Ad, and LMW-Ad isoforms (Alpco Diagnostics, Salem, 
NH). Estimated glomerular filtration rate (eGFR) was 
estimated according to creatinine-clearance using the 
Cockcroft-Gault formula. 
 
Statistical analysis 
 
Patients’ characteristics were reported as mean and 
standard deviation (±SD) or median and Inter-Quartile-
Range (IQR) for continuous variables as appropriate. 
Frequencies and percentages were used for categorical 
ones. Correlations between continuous variables were 
estimated using Spearman correlation. Time-to-event data 
were analyzed by means of log-rank test or univariate 
Cox-models for categorical or continuous variables, 
respectively. Significance of LMW-Ad was also assessed 
at multivariate Cox-modeling, after adjusting for possible 
relevant confounders. The maximum events to number of 
predictors ratio was fixed at fifteen, and the model was 
chosen by minimizing the Akaike Information Criterion 
(AIC) in a forward fashion. The following clinical 
mortality predictors were considered for final inclusion: 
age, sex, smoke, BMI, previous CHD, blood pressure, 
triglycerides, creatinin, fasting glucose, fasting insulin, 
HOMA IR, eGFR, HDL, LDL. Total-Ad, HMW-Ad, 
MMW-Ad, and LMW-Ad were forced in the model and 
considered separately for each of four multivariable Cox-
regression models. 
 
RESULTS 
 
Clinical characteristics of patients are summarized in 
Table 1. During follow-up (76.4 ± 37.3 months) 54 deaths 
occurred, corresponding to an overall annual incidence 
rate of 8.7%. Of those patients, 8 died for cardiovascular 
events (2 fatal-strokes and 6 fatal-myocardial-
infarctions). When compared with the remaining 
participants, subjects who died during follow-up were 
older, more frequently men, had a higher prevalence of 
smoking habit and previous coronary artery disease but a 
similar rate of diabetes, eGFR and equivalent BMI, lipid 
profile, high-sensitivity CRP and TNF-α. Among 
Adiponectin isoforms, only LMW-Ad levels were 
significantly higher in subjects who died during follow up 
(2.3µg/ml vs 1.4µg/ml, respectively, p:0.024) (Table 1). 
Only in diabetic subjects LMW-Ad was positively 
associated with insulin resistance evaluated by HOMA IR 
(r:0.452, p:0.007) and in overall population LMW-Ad was 
significantly higher in male subjects (p:0.047) and in 
individuals with previous CHD (p:0.026) (data not 
showed). 
Elevated levels of LMW-Ad were significantly 
associated with all-cause mortality (HR:1.13, 
95%CI:1.05-1.22, p:0.002) whereas Total-, HMW- and 
MMW-Ad did not. To avoid possible confounding 
factors, we created four multivariate models, each for 
every adiponectin isoforms. After adjustment of 
covariates, including sex, age, and previous history of 
CHD, while neither Tot-Ad, nor HMW-Ad and MMW-
Ad were associated with mortality (Table 2, Models 1,2 
and 3), the hazard ratio for LMW-Ad was 1.11, again 
significant (95%CI:1.02-1.21; p:0.017) (Table 2, Model 
4). 
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Table 1. Baseline clinical and laboratory characteristics of patients divided upon follow-up mortality. Data are 
displayed as n (%) or mean (±SD). 
 All-cause deaths (n°54) Survivors (n°43) p 
Age (years)  80.4±3.8 78.5±3.3 <0.05 
Gender (male) 39(72.2) 21(48.8) <0.056 
BMI (kg/m²) 26.8±3.5 27.0±4.3 0.841 
Systolic blood pressure (mmHg) 144.8±21.4 146.5±21.4 0.712 
Diastolic blood pressure (mmHg) 75.6±12.4 77.6±10.0 0.427 
Total cholesterol (mg/dl) 183.3±38.3 188.3±39.8 0.572 
High-density-lipoprotein cholesterol (mg/dl) 48.7±13.2 54.3±14.7 0.085 
Low-density-lipoprotein cholesterol (mg/dl) 118.3±32.8 116.5±34.7 0.813 
Triglycerides (mg/dl)  123.8±61.6 110.3±37,3 0.220 
Current or former smokers (yes) 32(59.2) 16(37.2) <0.05 
Diabetes (yes) 20(37.0) 11(25.5) 0.229 
Stable CHD (yes) 24(44.4) 10(23.2) <0.050 
Tumor necrosis factor-α (pg/ml) 12.9±15.0 11.9±14.1 0.757 
High sensitivity C-reactive protein (mg/l) 5.0±5.6 3.3±3.8 0.083 
Estimated glomerul filtration rate (ml*sec-¹) 
 
57.1±19.9 59.5±19.0 0.595 
Total-Adiponectin (µg/ml) 4.7±4.2 4.6±4.1 0.896 
HMW-Ad (µg/ml) 1.7±1.8 2.3±2.3 0.222 
MMW-Ad (µg/ml) 1.0±1.0 1.1±1.3 0.831 
LMW-Ad (µg/ml) 2.5±2.5 1.4±1.4 <0.05 
Pharmacological Therapy    
Metformin* (%) 75 72 0.889 
Sulphonylurea* (%) 25 36 0.504 
Glitazone* (%) 10 27 0.210 
Angiotensin-converting enzyme inhibitor or 
angiotensin II receptor antagonist (%) 
77 83 0.826 
 
Diuretic (%) 35 25 0.309 
Calcium antagonist (%) 35 34 0.975 
Beta-blocker (%) 50 42 0.424 
Aspirin (%) 60 63 0.723 
Statin (%) 57 55 0.942 
 
CHD: coronary heart disease; HMW-Ad: High Molecular Weight-Adiponectin; MMW-Ad: Medium Molecular Weight-Adiponectin; LMW-Ad: 
Low Molecular Weight-Adiponectin 
*Therapy referred to only diabetic subjects 
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Table 2. Multivariate analysis models for all-cause mortality with all Adiponectin isoforms. 
 HR CI (95%) p 
 
Model 1 
Gender (male) 2.04 1.17-3.58 0.012 
Age (year) 1.10 1.01-1.19 0.019 
Stable CHD (yes) 1.45 0.80-2.64 0.220 
Total-Adiponectin (µg/ml) 0.99 0.93-1.05 0.663 
 Model 2 
Gender (male) 2.03 1.16-3.55 0.013 
Age (year) 1.10 1.01-1.19 0.026 
Stable CHD (yes) 1.45 0.80-2.65 0.220 
HMW-Ad (µg/ml) 0.91 0.80-1.04 0.173 
 Model 3 
Gender (male) 2.05 1.16-3.64 0.014 
Age (year) 1.10 1.02-1.19 0.014 
Stable CHD (yes) 1.35 0.73-2.49 0.337 
MMW-Ad (µg/ml) 1.04 0.82-1.32 0.723 
 Model 4 
Gender (male) 1.91 1.08-3.35 0.025 
Age (year) 1.10 1.02-1.20 0.013 
Stable CHD (yes) 1.22 0.67-2.21 0.51 
LMW-Ad (µg/ml) 1.11 1.02-1.21 0.017 
 
CHD: coronary heart disease; HMW-Ad: High Molecular  
Weight-Adiponectin; MMW-Ad: Medium Molecular Weight-Adiponectin; 
LMW-Ad: Low Molecular Weight-Adiponectin 
DISCUSSION  
In this prospective study, after adjustment for 
cardiovascular mortality risk factors, we found a 
significant association between elevated levels of LMW-
Ad and increased all-cause mortality in elderly patients.  
The predictive capacity of LMW-Ad remained 
following adjustments for age, sex, and stable CHD. Of 
note, neither Tot-Ad, nor HMW-Ad and MMW-Ad were 
associated with all-cause mortality. Actually, subjects 
who died during the follow up had a large proportion of 
men than remaining participants. Generally, men have a 
shortened life expectancy. Thus, it is possible that this 
difference of gender may give a significant effect on 
mortality risk than that of LMW-adiponectin. 
Nevertheless, the predictive capacity of LMW-Ad 
remained significant even when survival analysis was 
performed only in male subjects (LogRank 4.44, p:0.035). 
To the best of our knowledge, this is the first report 
concerning the relathionship between multimeric 
adiponectin forms and mortality in aged people. Previous 
studies linking adiponectin levels and mortality in older 
adults have taken into account only Tot-Ad concentration, 
missing to investigate the distribution of adiponectin 
isoforms.  
The mechanism behind the positive association of 
Tot-Ad and mortality is not fully understood and at a first 
glance seems contradictory as adiponectin has anti-
inflammatory and anti-atherogenic properties. This 
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particular relationship has been described as a paradox 
[1]. 
Nevertheless, in specific cell types, adiponectin 
exerts some deleterious effects on processes involved in 
atherogenesis and in oncogenesis, including stimulatory 
effect on secretion of pro-inflammatory cytokines and 
angiogenesis [5-7]. Furthermore, some reports concluded 
that increased plasma adiponectin level is an independent 
risk for dementia and Alzheimer disease in human cohorts 
[8].  
A significant increase of adiponectin is reported in 
chronic inflammatory related disease such as rheumatoid 
arthritis, systemic lupus erythematosus, inflammatory 
bowel diseases, allergy and asthma [9]. 
However, since our results come from elderly 
subjects it is intriguing to speculate that, in a state of 
healthy aging without critical vascular, proliferative or 
infective diseases, adiponectin levels may be suppressed 
or lead anti-inflammatory signals, while in frailer patient 
adiponectin may be driven upward as an attempt of a 
natural defense and determine the activation of 
detrimental signals beside the well-known anti-
inflammatory pathways. Whether Adiponectin Receptor 1 
and 2 play different roles in this context is unknown, 
although recently it has been shown that the two receptors 
extert opposite effects on cancer progression [10-11]. The 
observed increase in LMW-Ad in our and other studies 
might be dependent from an impaired multimerization 
process, that is observed in chronic disorders such as 
diabetes and during aging. Consistently, a recent cross-
sectional study in subjects with RA showed that LMW-
Ad is associated with disease activity [12]. 
Our study has some limitations. First, the study 
enrolled a limited number of subjects although included a 
follow up for mortality having adiponectin multimers data 
available at baseline. Second, it is possible that subjects 
with low LMW-Ad levels were already dead at the 
beginning of the study, affecting the main result. 
Consequently, it is feasible that LMW-Ad plays an 
indirect effect on total mortality, that may be related to the 
age of the subjects. Third, low HMW-Ad was higher in 
survivors but not significantly associated to mortality and 
we cannot exclude that this is dependent by the number of 
events or subjects in our study. 
In previous report [4] we observed that LMW-Ad 
was significantly higher in CAD subjects without renal 
and heart failure. Nevertheless, although it is possible that 
LMW-Ad might be protecting especially to the heart and 
vasculature, due to the limited numbers of CV deaths, this 
work does not support a specific cardiovascular role for 
LMW-Ad. Finally, the study was from a single European 
district, but it is known that adiponectin levels differ 
according to ethnicity.  
In conclusion, our pilot observation in elderly 
subjects suggests that measuring LMW-Ad levels may 
help to improve the risk of all cause mortality, a finding 
that might deserve replication in larger cohorts and 
different ethnicities.  
 
Acknowledgements 
 
This manuscript was supported in part by the following 
grants: PRIN 2015MPESJS_004, RF-2011-02349921 and 
Fondazione-Roma NCD call 2014 (all to M.F.). 
 
References 
 
[1] Ortega-Moreno L, Copetti M, Fontana A, De Bonis 
C, Salvemini L, Trischitta et al. (2016). Evidence of a 
causal relationship between high serum adiponectin 
levels and increased cardiovascular mortality rate in 
patients with type 2 diabetes. Cardiovasc Diabetol, 
15:17. 
[2] Inoue T, Kotooka N, Morooka T, Komoda H, Uchida 
T, Aso Y et al. (2007). High-molecular-weight 
adiponectin as a predictor of long-term clinical 
outcome in patients with coronary artery disease. Am 
J Cardiol, 100: 569-74.  
[3] Kizer JR, Benkeser D, Arnold AM, Djousse L, Zieman 
SJ, Mukamal KJ, et al. (2013). Total and high-
molecular-weight adiponectin and risk of coronary 
heart disease and ischemic stroke in older adults. J Clin 
Endocrinol Metab, 98:255-63. 
[4] Rizza S, Gigli F, Galli A, Micchelini B, Lauro D, 
Lauro R et al. (2010). Adiponectin Isoforms in Elderly 
Patients with or without CHD. JAGS, 58: 702-706 
[5] Jia Z, Liu Y, Cui S (2014). Adiponectin induces breast 
cancer cell migration and growth factor expression. 
Cell Biochem Biophys 70(2): 1239-45. 
[6] Fayad R, Pini M, Sennello JA, Cabay RJ, Chan L, Xu 
A et al. (2007). Adiponectin deficiency protects mice 
from chemically induced colonic inflammation. 
Gastroenterology 132(2): 601-14. 
[7] Kaur K, Saxena A, Larsen B, Truman S, Biyani 
N, Fletcher E et al. (2015). Mucus mediated protection 
against acute colitis in adiponectin deficient mice. J 
Inflamm (Lond), 12:3 5.  
[8] Van Himbergen TM, Alexa SB, Ai M, Seshadri 
S, Otokozawa S, Au R et al. (2012). Biomarkers for 
insulin resistance and inflammation and the risk for 
all-cause dementia and alzheimer disease results from 
the framingham heart study. Arch Neurol, 69, 564-600 
[9] Matsumoto Y, Toyomasu K, Uchimura N, Ishitake T 
(2013). Low-molecular-weight adiponectin is more 
closely associated with episodes of asthma than high-
molecular-weight adiponectin. Endocr J, 60:119-25 
[10] Tsukada T, Fushida S, Harada S, Terai S, Yagi 
Y, Kinoshita J et al. (2011). Adiponectin receptor-1 
 Rizza S., et al                                                                                             Low molecular weight Adiponectin and aging 
Aging and Disease • Volume 9, Number 5, October 2018                                                                               951 
 
expression is associated with good prognosis in gastric 
cancer. J Exp Clin Cancer Res, 30: 107 
[11] Rider JR, Fiorentino M, Kelly R, Gerke T, Jordahl 
K, Sinnott JA et al. (2015). Tumor expression of 
adiponectin receptor-2 and lethal prostate cancer.  
Carcinogenesis, 36(6): 639-47.  
[12] Ping Li, Li Yang, Cui-li Ma, Liu B, Zhang X, Ding R 
et al. (2015). Low-molecular-weight adiponectin is 
more closely associated with disease activity of 
rheumatoid arthritis than other adiponectin multimeric 
forms. Clin Rheumatol, 34:1025-1030 
 
 
 
